Watchlist

Watchlist
Aptose Biosciences, Inc. (APTO)
Aptose Biosciences, Inc. (APTO)
Aptose Approaching The Clinic With 2 Very Interesting Assets
It has been a long road, but Aptose ( APTO ) is closing in on getting its two lead drugs into clinical trials. The company still has to resolve a manufacturing-related clinical hold for APTO-253 and finish its pre-IND work on CG806, but Aptose should have both compounds in human test…
Aptose Biosciences' (APTO) CEO William Rice on Q1 2018 Results - Earnings Call Transcript
Aptose Biosciences Inc. (APTO) Q1 2018 Earnings Conference Call May 10, 2018 17:00 P.M. ET Executives Susan Pietropaolo - SMP Communications William G. Rice - Chairman, President, and CEO Gregory Chow - SVP and CFO Analysts John Newman - Canaccord Genuity Joseph Pantginis…
Aptose Biosciences misses by $0.11
Aptose Biosciences (NASDAQ: APTO ): Q1 EPS of -$0.23 misses by $0.11 . More news on: Aptose Biosciences Inc., Earnings news and commentary, Healthcare stocks news, , Read more …
Aptose Bio's CG'806 shows encouraging action in preclinical studies; shares ahead 6%
Aptose Biosciences ( APTO +6.1% ) is up in early trade on the heels of its announcement of encouraging preclinical data on pan-FLT3/pan-BTK inhibitor CG'806 in certain blood cancers. The results were presented at the American Association for Cancer Research Annual Meeting in Chicago. M…
Premarket Gainers as of 9:05 am (04/16/2018)
DVAX +13% as investors bullish on early-stage data on Dynavax's SD-101 + Keytruda in advanced melanoma. More news on: Dynavax Technologies Corporation, Alkermes plc, Eldorado Resorts, Inc., Stocks on the move, , Read more …
Aptose Biosciences (APTO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
The following slide deck was published by Aptose Biosciences Inc. in conjunction with this Read more …
Aptose Bioscience: An In-Depth Look At Valuation
Aptose Biosciences ( APTO ) is a small biopharmaceutical company, worth approximately $100 million, with shares that trade for ~$3 a piece. Since their lead drug candidate, APTO-253, was placed on clinical hold due to a manufacturing issue, the stock price has been subdued as institutions hav…
Key events next week - healthcare
Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more …
Your Daily Pharma Scoop: Sorrento Sell-Off, Bluebird/Celgene Agreement, Edge Therapeutics' Setback
A nalysis focus: Sorrento Sorrento Therapeutics (SRNE) shares are down nearly 25%. Shares have been dragged lower by the convertible debt deal announced on Tuesday, as well as, a cautious article published on Seeking Alpha. The article published by J Capital raises sev…
Aptose Biosciences' (APTO) CEO William Rice on Q4 2017 Results - Earnings Call Transcript
Aptose Biosciences Inc. (APTO) Q4 2017 Results Earnings Conference Call March 27, 2018, 05:00 PM ET Executives Michael Wood - LifeSci Advisors William Rice - Chairman, President and CEO Gregory Chow - SVP and CFO Analysts Jotin Marango - ROTH Capital Partners John Newman …
Aptose Biosciences, Inc. (APTO)